Evidence map›Paper›PMID 25766675›Full record

ArticleNeurobiology of disease2015

SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.

Sierk Haenisch, Yi Zhao, Aparna Chhibber, Kitti Kaiboriboon, Lynn V Do, Silke Vogelgesang, Nicholas M Barbaro, Brian K Alldredge, Daniel H Lowenstein, Ingolf Cascorbi and 1 more

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Overexpression of mGluMolecular neurobiology · 2025
    Article
  4. Profiling the Impact of mGluACS chemical neuroscience · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Implications of aCurrent issues in molecular biology · 2024
    Article
  9. Review
  10. The lactate metabolism and protein lactylation in epilepsy.Frontiers in cellular neuroscience · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Sierk HaenischSchool of Pharmacy, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA; Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. Electronic address: haenisch@pharmakologie.uni-kiel.de.
Yi ZhaoDepartment of Nuclear Medicine, Molecular Imaging and Therapy, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Aparna ChhibberSchool of Pharmacy, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Kitti KaiboriboonSwedish Epilepsy Center, Neuroscience Institute, Seattle, WA, USA.
Lynn V DoClinical Pharmacy Services, Medical Center, University of California, San Francisco, CA, USA; School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, CA, USA.
Silke VogelgesangDepartment of Neuropathology, Institute of Pathology, University of Greifswald, Greifswald, Germany.
Nicholas M BarbaroDepartment of Neurological Surgery and Neurology, School of Medicine, Indiana University, Indianapolis, IN, USA.
Brian K AlldredgeSchool of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, CA, USA; School of Medicine, Department of Neurology, University of California, San Francisco, CA, USA.
Daniel H LowensteinSchool of Medicine, Department of Neurology, University of California, San Francisco, CA, USA.
Ingolf CascorbiInstitute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Deanna L KroetzSchool of Pharmacy, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
University of California, San Francisco · USIndiana University – Purdue University Indianapolis · USSwedish Medical Center · USUniversität Greifswald · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Lübeck · DE

Funding

PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YEE, SOOK WAH · 2010 to 2014
$16.3M
NIGMS NIH HHS GM61390NIGMS NIH HHS U01 GM061390NIGMS NIH HHS U19 GM061390
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally control the expression of their target genes via RNA interference. There is increasing evidence that expression of miRNAs is dysregulated in neuronal disorders, including epilepsy, a chronic neurological disorder characterized by spontaneous recurrent seizures. Mesial temporal lobe epilepsy (MTLE) is a common type of focal epilepsy in which disease-induced abnormalities of hippocampal neurogenesis in the subgranular zone as well as gliosis and neuronal cell loss in the cornu ammonis area are reported. We hypothesized that in MTLE altered miRNA-mediated regulation of target genes could be involved in hippocampal cell remodeling. A miRNA screen was performed in hippocampal focal and non-focal brain tissue samples obtained from the temporal neocortex (both n=8) of MTLE patients. Out of 215 detected miRNAs, two were differentially expressed (hsa-miR-34c-5p: mean increase of 5.7 fold (p=0.014), hsa-miR-212-3p: mean decrease of 76.9% (p=0.0014)). After in-silico target gene analysis and filtering, reporter gene assays confirmed RNA interference for hsa-miR-34c-5p with 3'-UTR sequences of GABRA3, GRM7 and GABBR2 and for hsa-miR-212-3p with 3'-UTR sequences of SOX11, MECP2, ADCY1 and ABCG2. Reporter gene assays with mutated 3'-UTR sequences of the transcription factor SOX11 identified two different binding sites for hsa-miR-212-3p and its primary transcript partner hsa-miR-132-3p. Additionally, there was an inverse time-dependent expression of Sox11 and miR-212-3p as well as miR-132-3p in rat neonatal cortical neurons. Transfection of neurons with anti-miRs for miR-212-3p and miR-132-3p suggest that both miRNAs work synergistically to control Sox11 expression. Taken together, these results suggest that differential miRNA expression in neurons could contribute to an altered function of the transcription factor SOX11 and other genes in the setting of epilepsy, resulting not only in impaired neural differentiation, but also in imbalanced neuronal excitability and accelerated drug export.

Indexed as

AdultAnimalsBrainCell Line, TumorCells, CulturedCerebral CortexComputer SimulationDrug Resistant EpilepsyFemaleGene Expression ProfilingHepatoblastomaHumansMaleMicroRNAsMiddle AgedOligonucleotide Array Sequence AnalysisMicroRNAsSOX11 protein, humanSOXC Transcription FactorsEpilepsyGABAGlutamatehsa-miR-34c-5pMicroRNAmiR-132-3pmiR-212-3pNeurogenesisNeuronal differentiationSOX11Temporal lobe

Identifiers

PMID25766675
PMCPMC4404495
OpenAlexW2068741167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.